This book explores the financial side of cancer immunotherapy, a revolutionary approach to fighting cancer. It breaks down the costs of various treatments, from checkpoint inhibitors to CAR T-cell therapy, oncolytic virus therapy, and beyond. It examines the development, production, and delivery costs of these cutting-edge therapies. The book also delves into the economics of newer treatments like bispecific antibodies, nanotechnology-based immunotherapy, and gene-editing approaches. It analyzes the factors influencing the cost and accessibility of these treatments. Finally, it offers strategies to make these potentially life-saving therapies more affordable.

This book goes beyond a simple overview of cancer treatment. It provides a deep dive into the financial complexities of immunotherapy, offering valuable insights for patients, healthcare professionals, and policymakers alike. Unlike other books that may focus solely on the science or the clinical aspects, this book tackles the often-overlooked financial dimension. It explores the economic barriers to accessing these innovative treatments and discusses potential solutions to ensure affordability and broader access. This book offers a unique and essential perspective on the fight against cancer.